We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Abbott won FDA approval for TactiFlex Duo, an AFib catheter offering PFA, RF energy or both.
Abbott's Electrophysiology sales rose 13.4% year over year in the second quarter of 2026.
TactiFlex Duo approval was based on FlexPulse IDE data showing favorable safety and effectiveness.
Abbott Laboratories (ABT - Free Report) recently received Food and Drug Administration (“FDA”) approval for the TactiFlex Duo Ablation Catheter to treat patients with atrial fibrillation (AFib). TactiFlex Duo represents an important advancement as the company builds the industry's most comprehensive electrophysiology portfolio.
Abbott will begin cases with broader commercial adoption across the country in the coming weeks.
Predicting ABT Stock Movement Following the News
Following the announcement, ABT’s shares edged down 2.6%, finishing at $105.52 yesterday.
In recent years, electrophysiology has rapidly evolved as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment. In the second quarter of 2026, Abbott’s Electrophysiology sales grew 13.4% year over year. We expect the latest FDA approval to drive positive market sentiment for ABT stock in the coming days.
Abbott has a market capitalization of $187.45 billion. The company’s earnings yield of 5.1% compares favorably with the industry’s 2.5%. In the trailing four quarters, it delivered an average earnings surprise of 0.8%.
About ABT’s TactiFlex Duo
TactiFlex Duo is the company’s latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy or a combination of both during a procedure, helping them tailor treatment to each patient's needs.
Abbott's EnSite X EP system provides physicians with real-time feedback and integrates the PFA Index, a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach helps create precise therapeutic lesions or small areas of scar tissue that block the abnormal electrical signals causing an irregular heartbeat while minimizing the impact on surrounding healthy tissue.
More Information on the FDA Approval
The FDA approval of TactiFlex Duo expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. The approval was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).
Industry Prospects Favor ABT
Per a report by Research Nester, the cardiac ablation market size was valued at $5.50 billion in 2025 and is set to exceed $17.86 billion by 2035, registering a CAGR of more than 12.5% during the forecast period (2026-2035). In 2026, the cardiac ablation market is estimated at $6.12 billion.
Image Source: Zacks Investment Research
Another Recent Development by ABT
Abbott launched Similac 360 Total Care Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. Its fat blend more closely resembles the fats in breast milk and it contains five immune-nourishing prebiotics to help support a baby's natural defenses. The product joins the company’s extensive portfolio of infant formulas.
ABT Stock Price Performance
Over the past year, ABT’s shares have plunged 20.1% compared with the industry’s 26.9% decline.
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% rise. Its earnings beat estimates in each of the trailing four quarters, with the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
Key Takeaways
Abbott Laboratories (ABT - Free Report) recently received Food and Drug Administration (“FDA”) approval for the TactiFlex Duo Ablation Catheter to treat patients with atrial fibrillation (AFib). TactiFlex Duo represents an important advancement as the company builds the industry's most comprehensive electrophysiology portfolio.
Abbott will begin cases with broader commercial adoption across the country in the coming weeks.
Predicting ABT Stock Movement Following the News
Following the announcement, ABT’s shares edged down 2.6%, finishing at $105.52 yesterday.
In recent years, electrophysiology has rapidly evolved as physicians adopt new technologies that improve the safety and effectiveness of AFib treatment. In the second quarter of 2026, Abbott’s Electrophysiology sales grew 13.4% year over year. We expect the latest FDA approval to drive positive market sentiment for ABT stock in the coming days.
Abbott has a market capitalization of $187.45 billion. The company’s earnings yield of 5.1% compares favorably with the industry’s 2.5%. In the trailing four quarters, it delivered an average earnings surprise of 0.8%.
About ABT’s TactiFlex Duo
TactiFlex Duo is the company’s latest ablation catheter designed to give physicians more flexibility when treating AFib. The technology allows physicians to use pulsed field ablation (PFA), radiofrequency (RF) energy or a combination of both during a procedure, helping them tailor treatment to each patient's needs.
Abbott's EnSite X EP system provides physicians with real-time feedback and integrates the PFA Index, a tool designed to assess lesion formation during ablation with TactiFlex Duo. The dual-energy approach helps create precise therapeutic lesions or small areas of scar tissue that block the abnormal electrical signals causing an irregular heartbeat while minimizing the impact on surrounding healthy tissue.
More Information on the FDA Approval
The FDA approval of TactiFlex Duo expands Abbott's portfolio of technologies designed to help physicians treat patients with cardiac arrhythmias. The approval was secured based on the results from Abbott's FlexPulse IDE study. Late-breaking data from the study showed favorable safety and effectiveness outcomes in patients with paroxysmal AFib (irregular heart rhythm episodes that come and go).
Industry Prospects Favor ABT
Per a report by Research Nester, the cardiac ablation market size was valued at $5.50 billion in 2025 and is set to exceed $17.86 billion by 2035, registering a CAGR of more than 12.5% during the forecast period (2026-2035). In 2026, the cardiac ablation market is estimated at $6.12 billion.
Image Source: Zacks Investment Research
Another Recent Development by ABT
Abbott launched Similac 360 Total Care Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. Its fat blend more closely resembles the fats in breast milk and it contains five immune-nourishing prebiotics to help support a baby's natural defenses. The product joins the company’s extensive portfolio of infant formulas.
ABT Stock Price Performance
Over the past year, ABT’s shares have plunged 20.1% compared with the industry’s 26.9% decline.
ABT’s Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% rise. Its earnings beat estimates in each of the trailing four quarters, with the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.